Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Capecitabine for Metastatic Colorectal Cancer
NCT02043821Unknown
- Sponsor
- Beijing Chaoyang Hospital
- Primary completion
- Jan 2016
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing Placebo with Capecitabine (2 arms). Primary endpoint: Duration of Disease Control at 2 years. Status: unknown.
02
Drugs
capecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02043821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043821.